ESMO 2025 | CheckMate 274: 5-year results of adjuvant nivolumab in MIUC
Clara Steiner, MD, Dana-Farber Cancer Institute, Boston, MA & University Hospital Leipzig, Leipzig, Germany, gives an overview of updated 5-year results from the Phase III CheckMate 274 trial (NCT02632409), comparing adjuvant nivolumab versus placebo in patients with high-risk muscle-invasive urothelial carcinoma (MIUC) after radical surgery. Sustained improvements in disease-free, overall, and disease-specific survival were observed with nivolumab, with no new safety concerns. Exploratory circulating tumor (ctDNA) analysis suggested greater benefit in ctDNA-positive patients, further supporting adjuvant nivolumab as a standard of care in this setting. This interview took place at the European Society for Medical Oncology (ESMO) 2025 Congress in Berlin, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
